Literature DB >> 21428778

Oral rivaroxaban for symptomatic venous thromboembolism.

Gijs W Landman, Reinold O B Gans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21428778     DOI： 10.1056/NEJMc1100734

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Therapeutic duplication of anticoagulants: a retrospective study of frequency and consequences in a tertiary referral hospital.

Authors:  Ramin Rahmanzade; Francisco Cabrera Diaz; Claudia Zaugg; Philipp Schuetz; Ali Reza Salili
Journal:  Thromb J       Date:  2020-08-03

2.  Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.

Authors:  Sadık Volkan Emren; Mehdi Zoghi; Rida Berilgen; İbrahim Halil Özdemir; Oğuzhan Çelik; Nurullah Çetin; Asım Enhoş; Cemal Köseoğlu; Abdurrahman Akyüz; Volkan Doğan; Fatih Levent; Yüksel Dereli; Tolga Doğan; Özcan Başaran; Ilgın Karaca; Özkan Karaca; Yılmaz Ömür Otlu; Çağlar Özmen; Selvi Coşar; Mutlu Sümerkan; Erdal Gürsul; Sinan İnci; Ersel Onrat; Oktay Ergene
Journal:  Bosn J Basic Med Sci       Date:  2018-05-20       Impact factor: 3.363

3.  Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing.

Authors:  Souad Moudallel; Stephane Steurbaut; Pieter Cornu; Alain Dupont
Journal:  Front Pharmacol       Date:  2018-10-30       Impact factor: 5.810

4.  Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands.

Authors:  Susan Hanemaaijer; Fong Sodihardjo; Annemieke Horikx; Michel Wensing; Peter A G M De Smet; Marcel L Bouvy; Martina Teichert
Journal:  Int J Clin Pharm       Date:  2015-08-05

5.  Platelet-derived porous nanomotor for thrombus therapy.

Authors:  Mimi Wan; Qi Wang; Rongliang Wang; Rui Wu; Ting Li; Dan Fang; Yangyang Huang; Yueqi Yu; Leyi Fang; Xingwen Wang; Yinghua Zhang; Zhuoyue Miao; Bo Zhao; Fenghe Wang; Chun Mao; Qing Jiang; Xingquan Xu; Dongquan Shi
Journal:  Sci Adv       Date:  2020-05-27       Impact factor: 14.136

6.  Rivaroxaban improves hidden blood loss, blood transfusion rate and reduces swelling of the knee joint in knee osteoarthritis patients after total knee replacement.

Authors:  Yi-Min Zhang; Jian-Yong Liu; Xue-Dong Sun; Miao Zhang; Xiao-Guang Liu; Xiu-Li Chen
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

7.  Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre.

Authors:  Anadil Faqah; Hassan Sheikh; Muhammad Abu Bakar; Fatima Tayyaab; Sahrish Khawaja
Journal:  Thromb J       Date:  2020-05-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.